Preclinical trials employing mouse xenograft models of prostate cancer have demonstrated that this technique effectively sustains BiTE plasma concentration and enhances tumor growth inhibition, especially in tumors exhibiting low PSMA expression [80,86]. This evidence concerns the gene FOLH1 and neoplasm.